Key result
T2D linked to ~30% greater 30-day bleeding risk after colorectal cancer surgery, but not VTE.
Why the study?
Bleeding and venous thromboembolism are adverse outcomes after colorectal cancer surgery, and type 2 diabetes clusters with risk factors for both.
Does Type 2 Diabetes increase the risk of bleeding and venous thromboembolism in patients undergoing colorectal cancer surgery?
Cohort (n=48,295)
Does Type 2 Diabetes increase the risk of bleeding and venous thromboembolism in patients undergoing colorectal cancer surgery?
Hazard Ratio: 1.3 (95% CI 1.1–1.53)
Absolute Event Rate: 2.7% vs 2%
In patients undergoing colorectal cancer surgery, preexisting Type 2 Diabetes is associated with a slightly increased risk of postoperative bleeding, likely driven by comorbidities, but not an increased risk of venous thromboembolism.
T2D-associated bleeding risk after colorectal cancer surgery warrants no practice change; leaves open independent effect versus comorbidities in prospective data.
Background Bleeding and venous thromboembolism (VTE) are adverse outcomes after colorectal cancer (CRC) surgery. Type 2 diabetes (T2D) clusters with bleeding and VTE risk factors. We examined the bleeding and VTE risk in patients with T2D undergoing CRC surgery and the prognosis after these adverse outcomes. Methods We conducted a prognostic population-based cohort study of 48,295 patients with and without T2D undergoing surgery for incident CRC during 2005 to 2019. Patients with T2D were diagnosed in a hospital setting or had redeemed a glucose-lowering drug prescription; the remaining cohort was patients without diabetes. We estimated the 30-day and 1-year risks of bleeding and VTE and used a Fine–Gray model to compute age-, sex-, and calendar year-adjusted subdistribution hazard ratios (SHRs). The Kaplan–Meier method was used to calculate 1-year mortality after bleeding or VTE. Results Within 30 days after CRC surgery, the risk of bleeding was 2.7% in patients with T2D and 2.0% in patients without diabetes (SHR: 1.30 [95% confidence interval [CI]: 1.10–1.53]). For VTE, the 30-day risks were 0.6% for patients with T2D and 0.6% for patients without diabetes (SHR: 1.01 [95% CI: 0.71–1.42]). The SHRs for bleeding and VTE within 1 year after CRC surgery were similar. The 1-year mortality was 26.0% versus 24.9% in the bleeding cohort and 25.8% versus 27.5% in the VTE cohort for patients with T2D versus without diabetes, respectively. Conclusion Although absolute risks were low, patients with T2D have an increased risk of bleeding but not VTE after CRC surgery.
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2024) conducted a cohort in Colorectal cancer (n=48,295). Type 2 diabetes vs. No diabetes was evaluated on 30-day risk of bleeding (SHR 1.30, 95% CI 1.10-1.53). Type 2 diabetes was associated with an increased 30-day risk of bleeding (2.7% vs 2.0%, SHR 1.30) but not venous thromboembolism after colorectal cancer surgery compared to patients without diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: